

Theme	Session Title	Presentation No.	Abstract No.	Lecture title	Speaker	Country
Tumor-type specific Sessions	AT/RT (basic)	ATRB-IS-01	SPKR-22	ATRT – update on biology, subgroups, targets, and potential clinical implications	Marcel Kool	Germany
		ATRB-O-02	ATRT-13	Different cells of origin pave the way for molecular heterogeneity in rhabdoid tumors	Monika Graf	Germany
		ATRB-O-03	ATRT-14	Macrophage-tumor cell interaction promotes ATRT progression and chemoresistance	Viktoria Melcher	Germany
		ATRB-O-04	ATRT-25	Integrated quantitative SWATH-MS proteomics analysis of ATRTs uncovers new therapeutic opportunities	Martina Finetti	USA
		ATRB-P-05	ATRT-24	Cell surface proteome analysis of ATRT identifies targets for immunotherapy	Siddhartha Mitra	USA
		ATRB-P-06	ATRT-06	SMARCB1 loss driven non-canonical PRC1 activity regulates differentiation in Atypical Teratoid Rhabdoid Tumors (ATRT).	Irina Alimova	USA
		ATRB-O-07	ATRT-33	Enabling rapid classification of ATRT with Nanostring nCounter platform	Ben Ho	Canada
		ATRB-P-08	ATRT-28	Single nuclei sequencing reveals the different phenotypic composition of the ATRT subgroups	Pascal Johann	Germany
		ATRB-O-09	ATRT-16	Modelling ATRT through SWI/SNF complex deficiency in genetically-engineered mouse models	Andrew Bondoc	Canada
		ATRB-O-10	ATRT-18	SHH-subtype Atypical Teratoid/Rhabdoid Tumors are selectively sensitive to gemcitabine treatment	Dennis Metselaar	Netherlands
		ATRB-P-11	ATRT-22	High-throughput drug screening of FDA-approved cancer drugs reveals potential therapeutic approaches for atypical teratoid rhabdoid tumour	Wai Chin Chong	Australia
		ATRB-O-12	ATRT-32	Genome-wide CRISPR and small-molecule screens uncover targetable dependencies in AT/RTs	Daniel Merk	Germany
		ATRB-P-13	ATRT-11	Prevalence of germline variants in SMARCB1 including somatic mosaicism in AT/RT and other rhabdoid tumors	Ryota Shirai	Japan
		ATRB-P-14	ATRT-15	LY6D – a candidate for nanoparticle-based targeted therapies of ATRT	Lea Hagemeyer	Germany
		ATRB-P-15	ATRT-19	Epigenetic reprogramming leads to innate immune pathway activation in AT/RT	Seethalakshmi Hariharan	USA
		ATRB-P-16	ATRT-27	Cost-effective assays to subgroup ATRT in the daily routine	María-Jesús Lobon-Iglesias	France
		ATRB-P-17	ATRT-03	Identification of microRNA-based prognostic biomarkers and candidate therapeutic agents for atypical teratoid/rhabdoid tumor	Yang Zhang	China
		ATRB-P-18	ATRT-20	CDK7 inhibition in AT/RT	Andrew Morin	USA
		ATRB-P-19	ATRT-23	The dual mTORC1/2 inhibitor Sapanisertib disrupts the NRF2-mediated stress response and combines synergistically with the BH3 mimetic Obatoclox to extend AT/RT survival	Jeffrey Rubens	USA
		ATRB-P-20	ATRT-01	Upregulation of protein synthesis and proteasome degradation confers sensitivity to proteasome inhibitor bortezomib in Myc-atypical teratoid/rhabdoid tumors	Minh-Huy Tran	Taiwan
		ATRB-P-21	ATRT-17	Targeting glutamine metabolism lowers methylation potentials in AT/RT and synergize with tazemetostat	Satoshi Nakata	USA
		ATRB-P-22	ATRT-02	MEK/ERK signalling dependency in atypical teratoid rhabdoid tumours	Hui (Claire) Shi	Australia
		ATRB-P-23	ATRT-09	Identification of hub genes in atypical teratoid/rhabdoid tumors by multiple-microarray analysis	Wei Liu	China
		ATRB-P-24	ATRT-21	Rhabdoid predisposition syndrome: report of molecular profiles and treatment approach in three children with synchronous atypical teratoid/rhabdoid tumor and malignant rhabdoid tumor	Margaret Shatara	USA
	AT/RT (clinical)	ATRC-P-01	ATRT-05	Results of multicenter trial concerning the treatment of children with Atypical Teratoid/Rhabdoid Tumors (ATRT) of the central nervous system	Olga Zheludkova	Russia
		ATRC-P-02	ATRT-08	A phase II study of continuous low dose panobinostat in paediatric patients with malignant rhabdoid tumors/atypical teratoid rhabdoid tumors	Paul Wood	Australia
		ATRC-P-03	ATRT-26	Meta-analysis of treatment modalities in metastatic atypical teratoid/rhabdoid tumors in children	Mohamed AbdelBaki	USA
		ATRC-P-04	ATRT-30	Retrospective analysis of children with atypical teratoid rhabdoid tumor treated according to ACNS0333	Lindsey Hoffman	USA
		ATRC-P-05	ATRT-07	High-dose chemotherapy and autologous stem cell transplantation for an adult presentation of the atypical teratoid-rhabdoid tumor (ATRT)	Maciej Mrugala	USA
		ATRC-P-06	ATRT-31	Successful multimodality management of ATRT of the lower dorsal spine with spinal drop metastasis	Ahitagni Biswas	India
		ATRC-P-07	ATRT-04	Inherited rhabdoid predisposition syndrome: a case of choroid plexus carcinoma and atypical teratoid rhabdoid tumor in siblings	Alexis Judd	USA
		ATRC-P-08	ATRT-10	Atypical teratoid/rhabdoid tumor of the pineal region in a pediatric patient	Carlos Almeida, Jr.	Brazil